Piper Jaffray upgrades St. Jude Medical (NYSE: STJ) from Neutral to Overweight with a $44 price target. The firm commented, "The stock has come in lately given concerns tied to the strengthening dollar. While a stronger dollar has the potential to trim our 2010 EPS outlook, we think it will be more than offset by incremental share gains in the U.S. ICD market due to the fallout from Boston Scientific's temporary sales stoppage. St. Jude's new CRM product pipeline could also further share gains. As such, we think STJ is at an attractive entry point for investors, hence our upgrade to an Overweight."